TY - JOUR
T1 - Clinical Practice Guidelines for Hepatocellular Carcinoma
T2 - The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines)
AU - The committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan
AU - Hasegawa, Kiyoshi
AU - Takemura, Nobuyuki
AU - Yamashita, Tatsuya
AU - Watadani, Takeyuki
AU - Kaibori, Masaki
AU - Kubo, Shoji
AU - Shimada, Mitsuo
AU - Nagano, Hiroaki
AU - Hatano, Etsuro
AU - Aikata, Hiroshi
AU - Iijima, Hiroko
AU - Ueshima, Kazuomi
AU - Ohkawa, Kazuyoshi
AU - Genda, Takuya
AU - Tsuchiya, Kaoru
AU - Torimura, Takuji
AU - Ikeda, Masafumi
AU - Furuse, Junji
AU - Akahane, Masaaki
AU - Kobayashi, Satoshi
AU - Sakurai, Hideyuki
AU - Takeda, Atsuya
AU - Murakami, Takamichi
AU - Motosugi, Utaroh
AU - Matsuyama, Yutaka
AU - Kudo, Masatoshi
AU - Tateishi, Ryosuke
N1 - Publisher Copyright:
© 2023 The Authors. Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology.
PY - 2023/5
Y1 - 2023/5
N2 - The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine and partly to the Grading of Recommendations Assessment, Development and Evaluation system, which was published in October 2021 in Japanese. In addition to surveillance–diagnostic and treatment algorithms, a new algorithm for systemic therapy has been created, as multiple drugs for hepatocellular carcinoma can be currently selected. Here, new or revised algorithms and evidence on which the recommendations are based are described.
AB - The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine and partly to the Grading of Recommendations Assessment, Development and Evaluation system, which was published in October 2021 in Japanese. In addition to surveillance–diagnostic and treatment algorithms, a new algorithm for systemic therapy has been created, as multiple drugs for hepatocellular carcinoma can be currently selected. Here, new or revised algorithms and evidence on which the recommendations are based are described.
KW - algorithm for surveillance and diagnosis
KW - algorithm for systemic therapy
KW - algorithm for treatment
KW - clinical practice guidelines
KW - hepatocellular carcinoma
UR - https://www.scopus.com/pages/publications/85150644822
UR - https://www.scopus.com/pages/publications/85150644822#tab=citedBy
U2 - 10.1111/hepr.13892
DO - 10.1111/hepr.13892
M3 - Article
AN - SCOPUS:85150644822
SN - 1386-6346
VL - 53
SP - 383
EP - 390
JO - Hepatology Research
JF - Hepatology Research
IS - 5
ER -
SDG 3 すべての人に健康と福祉を